Cargando…

Characterization of Teicoplanin-Specific T-Cells from Drug Naïve Donors Expressing HLA-A*32:01

[Image: see text] Teicoplanin is a glycopeptide antibiotic deployed to combat Gram-positive bacterial infection and has recently been associated with development of adverse drug reactions, particularly following previous exposure to vancomycin. In this study, we generated teicoplanin-specific monocl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardner, Joshua, Ogese, Monday, Betts, Catherine J., Pirmohamed, Munir, Naisbitt, Dean J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007560/ https://www.ncbi.nlm.nih.gov/pubmed/35107993 http://dx.doi.org/10.1021/acs.chemrestox.1c00425

Ejemplares similares

Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
por: Ogese, Monday O, et al.
Publicado: (2021)

Abs No: HLA-A*31:01 positive hypersensitive patient
por: Lichtenfels, Maike, et al.
Publicado: (2014)

HLA-DQ restricted activation of nitroso-sulfamethoxazole-specific CD4+ T-lymphocytes
por: Ogese, Monday, et al.
Publicado: (2014)

Establishment of an HLA-typed cohort of 1000 healthy blood donors and use of a dendritic cell priming assay to prime naive T cells to structurally divergent drugs
por: Faulkner, Lee, et al.
Publicado: (2014)

Dapsone‐ and nitroso dapsone‐specific activation of T cells from hypersensitive patients expressing the risk allele HLA‐B*13:01
por: Zhao, Qing, et al.
Publicado: (2019)

The HLA-A*31:01 allele: influence on carbamazepine treatment
por: Yip, Vincent Lai Ming, et al.
Publicado: (2017)

Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01
por: Pratoomwun, Jirawat, et al.
Publicado: (2021)

Activation of human CD8+ T-cells with nitroso dapsone-modified HLA-B*13:01-binding peptides()
por: Almutairi, Mubarak, et al.
Publicado: (2023)

Characterization of Drug-Specific CD4(+) T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions
por: Jaruthamsophon, Kanoot, et al.
Publicado: (2023)

Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury
por: Saide, Katy, et al.
Publicado: (2014)

Negative regulation by Programmed Death Ligand-1 during drug-specific priming of T-cells and the influence of Programmed Death-1 on effector T-cell function
por: Gibson, Andrew, et al.
Publicado: (2014)

Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
por: Hammond, Sean, et al.
Publicado: (2021)

In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers
por: Alfirevic, Ana, et al.
Publicado: (2012)

HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
por: Satapornpong, Patompong, et al.
Publicado: (2021)

Skewing of the TCR V repertoire in SMX-NO specific T cell responses
por: Faulkner, Lee, et al.
Publicado: (2014)

Drug Induced Hypersensitivity and the HLA Complex
por: Alfirevic, Ana, et al.
Publicado: (2010)

CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population
por: Carr, Daniel, et al.
Publicado: (2014)

T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab
por: Hammond, Sean, et al.
Publicado: (2021)

HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease
por: Hosseini, Ehteramolsadat, et al.
Publicado: (2023)

Chemical modification of the 6'-amino cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell activation without loss of antiviral activity
por: Alhaidari, Mohammad, et al.
Publicado: (2014)

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
por: Martínez Buitrago, Ernesto, et al.
Publicado: (2019)

Exosomal Transport of Hepatocyte‐Derived Drug‐Modified Proteins to the Immune System
por: Ogese, Monday O., et al.
Publicado: (2019)

Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics
por: Ade, Catherine M, et al.
Publicado: (2023)

Detection of Hepatic Drug Metabolite-Specific T-Cell Responses Using a Human Hepatocyte, Immune Cell Coculture System
por: Ali, Serat-E, et al.
Publicado: (2023)

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
por: Khor, Seik-Soon, et al.
Publicado: (2021)

Characterization of amoxicillin and clavulanic-acid-responsive CD4+ And CD8+ T-cells in patients with co-amoxiclav-induced liver injury
por: Kim, Seung-Hyun, et al.
Publicado: (2014)

Teicoplanin pharmacokinetics during albumin dialysis
por: Weiler, Stefan, et al.
Publicado: (2010)

Is Therapeutic Drug Monitoring of Teicoplanin Useful?
por: Kim, Shin-Woo
Publicado: (2014)

Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
por: Scholz, Erika Margaret, et al.
Publicado: (2017)

Tools for the Individualized Therapy of Teicoplanin for Neonates and Children
por: Ramos-Martín, V., et al.
Publicado: (2017)

Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection
por: Krummey, Scott M., et al.
Publicado: (2022)

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
por: Workum, J D, et al.
Publicado: (2020)

Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant
por: Kamburova, E. G., et al.
Publicado: (2018)

Therapeutic Drug Concentrations of Teicoplanin in Clinical Settings
por: Nah, So-Yun, et al.
Publicado: (2014)

Synthesis of Antiviral Perfluoroalkyl Derivatives of Teicoplanin and Vancomycin
por: Bereczki, Ilona, et al.
Publicado: (2020)

Teicoplanin: an alternative drug for the treatment of COVID-19?
por: Baron, Sophie Alexandra, et al.
Publicado: (2020)

Clinical outcomes of teicoplanin use in the OPAT setting
por: Dabrowski, Hannah, et al.
Publicado: (2020)

The First Dimeric Derivatives of the Glycopeptide Antibiotic Teicoplanin
por: Bereczki, Ilona, et al.
Publicado: (2022)

HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02
por: Martín, Paloma, et al.
Publicado: (2015)

Identification of Functional HLA-A*01:01–Restricted Epstein-Barr Latent Membrane Protein 2–Specific T-Cell Receptors( )
por: Huisman, Wesley, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_klb3toh2l9quplo05qkj04cth5